Literature DB >> 21571622

Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.

Z Samra1, S Rosenberg, M Dan.   

Abstract

The in vitro activity of tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin was tested against 63 clinical isolates of Ureaplasma urealyticum. The minimal inhibitory concentrations (MICs) and the minimal bactericidal concentrations (MBCs) were determined by the broth microdilution method in A7 medium. The MIC(50) and MIC(90) of the tested agents after 24 h of incubation were as follows: tetracycline, 0.5 and 2.0 μg/ml; doxycycline, 0.125 and 0.25 μg/ml; erythromycin, 2.0 and 8.0 μg/ml; roxithromycin, 2.0 and 4.0 μg/ml; clarithromycin, 0.25 and 1.0 μg/ml; azithromycin, 2.0 and 4.0 μg/ml; levofloxacin, 1.0 and 2.0 μg/ml; and moxifloxacin, 0.5 and 0.5 μg/ml, respectively. The MIC values after 24 h and 48 h incubation differed by no more than one dilution for all the agents with the exception of doxycycline (two dilution difference for MIC(90)). Overall, moxifloxacin was the most active agent in vitro against U. urealyticum, with the narrowest difference between MIC and MBC values, followed closely by levofloxacin. Clarithromycin was the most active macrolide. © E.S.I.F.T. srl - Firenze

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571622     DOI: 10.1179/joc.2011.23.2.77

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  11 in total

Review 1.  Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.

Authors:  Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

2.  Bilateral periprosthetic joint infection with Ureaplasma urealyticum in an immunocompromised patient.

Authors:  R L Roerdink; C M Douw; A C A P Leenders; R S Dekker; M Dietvorst; C J M Oosterbos; H T J Roerdink; R W T M Kempen; L P A Bom
Journal:  Infection       Date:  2016-05-28       Impact factor: 3.553

3.  A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Chan-Wook Park; Joong Shin Park; Jong Kwan Jun; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-09-16

4.  Prevalence and antibiotic susceptibility of Ureaplasma urealyticum and Mycoplasma hominis in Xi'an, China.

Authors:  X-Y Zeng; N Xin; X-N Tong; J-Y Wang; Z-W Liu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-16       Impact factor: 3.267

5.  Efficacy of standard therapies against Ureaplasma species and persistence among men with non-gonococcal urethritis enrolled in a randomised controlled trial.

Authors:  Christine M Khosropour; Lisa E Manhart; Catherine W Gillespie; M Sylvan Lowens; Matthew R Golden; Nicole L Jensen; George E Kenny; Patricia A Totten
Journal:  Sex Transm Infect       Date:  2015-01-23       Impact factor: 3.519

6.  Brain abscess caused by Ureaplasma urealyticum in an adult patient.

Authors:  Philipp Deetjen; Christoph Maurer; Andreas Rank; Ansgar Berlis; Sören Schubert; Reinhard Hoffmann
Journal:  J Clin Microbiol       Date:  2013-12-11       Impact factor: 5.948

7.  Role of biofilm formation in Ureaplasma antibiotic susceptibility and development of bronchopulmonary dysplasia in preterm neonates.

Authors:  Katherine Pandelidis; Amanda McCarthy; Kirsty L Chesko; Rose M Viscardi
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

8.  Antibiotic administration reduces the rate of intraamniotic inflammation in preterm prelabor rupture of the membranes.

Authors:  Marian Kacerovsky; Roberto Romero; Martin Stepan; Jaroslav Stranik; Jan Maly; Lenka Pliskova; Radka Bolehovska; Vladimir Palicka; Helena Zemlickova; Helena Hornychova; Jiri Spacek; Bo Jacobsson; Percy Pacora; Ivana Musilova
Journal:  Am J Obstet Gynecol       Date:  2020-07       Impact factor: 10.693

9.  Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China.

Authors:  Hui Pang; Guilian Li; Xiuqin Zhao; Haican Liu; Kanglin Wan; Ping Yu
Journal:  Biomed Res Int       Date:  2015-08-13       Impact factor: 3.411

10.  Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey.

Authors:  Claudia Pansieri; Chiara Pandolfini; Valery Elie; Mark A Turner; Sailesh Kotecha; Evelyne Jacqz-Aigrain; Maurizio Bonati
Journal:  Sci Rep       Date:  2014-02-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.